Eftilagimod Alpha Novel Triplet Combination is Well Tolerated, Generates CRs in Soft Tissue Sarcoma. #oncology #sarcoma
onclive.com/view/eftilagim…

Thank you to Eddy Sunarto for taking a close look at our recent trial results in soft tissue sarcoma for The The Australian.
#LAG3 #immunotherapy

theaustralian.com.au/business/stock…

Immutep is pleased to share positive initial clinical data reported from our efti combined with radiotherapy and checkpoint inhibitor, from our phase II trial in soft tissue sarcoma.

Read the full announcement here: bit.ly/44nk70Y

#clinicaltrials #LAG3 $IMM $IMMP

Eftilagimod alpha plus pembrolizumab as frontline therapy demonstrated preliminary responses and disease control in a small cohort of patients with recurrent or metastatic PD-L1–negative head and neck squamous cell carcinoma. #hncsm

cancernetwork.com/view/eftilagim…

Immutep shares its Quarterly Report for Q3 FY24, highlights:
· First clinical data from AIPAC-003 in breast cancer
· Positive preliminary response rate in head & neck cancer
· IMP761 entering clinical trials mid-CY2024
#LAG3 $IMM $IMMP
bit.ly/3y0rWO8

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC #hncsm #oncology onclive.com/view/eftilagim…

Shares of Australian biotechnology firm Immutep $IMM rise as much as 11.7% to A$0.430, highest level since March 24, 2022. Announces positive preliminary topline results from TACTI-003 phase IIB trial to evaluate drug therapy to treat head and neck squamous cell carcinoma.

Immutep announces positive preliminary topline results from our TACTI-003 Phase IIb trial evaluating efti in combination with MSD's KEYTRUDA® in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
bit.ly/49PCAnN

Immutep has appointed leading research institute, the CHDR, to perform its first-in-human clinical study of its autoimmune candidate, IMP761.

The trial is expected to begin mid-CY2024.
#LAG3 #autoimmunedisease $IMM $IMMP

ASX announcement: bit.ly/3Q60lRE

Immutep is pleased to announce it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority on our upcoming TACTI-004 Phase III trial.

bit.ly/3W0Cvue

#clinicaltrials #LAG3 #biotechnology $IMM $IMMP

On his recent visit to Sydney, Immutep CEO Marc Voigt caught up with the Finance News Network to talk about the Company's recent updates and clinical news. Watch the video here.
#LAG3 #immunotherapy $IMM $IMMP

youtu.be/gsmtHuSGTyQ?si… via YouTube

You can read a great summary of our recent breast cancer results from OncLive.com in their article below.
#LAG3 #immunotherapy

onclive.com/view/eftilagim…

📰 Member news

🤝 Telix Pharmaceuticals entered into an agreement to acquire @ARTMS_Inc

💰 La Trobe University received funding from the Mason Foundation

📝 Immutep announces first clinical data from 90mg dosing of efti

➡️ ow.ly/zz7P50QRPYp

Immutep is delighted to announce the first clinical data from the higher 90mg dose of efti. The data is from the safety lead-in part of the Phase II/III AIPAC-003 trial.

#LAG3 #immunotherapy $IMM $IMMP
Announcement: bit.ly/3In4tIP

Immutep is pleased to share its 2024 Half Year Report with shareholders including an update on its products, trials and partners.

#biotechnology #lag3 #clinicaltrials $IMM $IMMP

Read the full report here: bit.ly/3IAkUBL

An exciting year lies ahead for Immutep's 2 first-in-class agonists to fight cancer and autoimmune disease: Efti (upcoming pivotal Ph3 trial) & IMP761 (launching a first-in-human clinical trial by mid-2024).

Read our Investor Update: bit.ly/42NeCru
#LAG3 $IMM $IMMP

Immutep is pleased to announce the appointment of Anne Anderson as independent non-executive director (NED) of Immutep Limited.

#biotechnology #lag3 #clinicaltrials $IMM $IMMP
bit.ly/3ODM3XS

Thanks to Andy Gracey from Australian Ethical Investment for highlighting Immutep in his latest chat with The Motley Fool.
#LAG3 $IMM $IMMP

fool.com.au/2024/01/27/3-e…

Immutep shares its Quarterly Report for Q2 FY24, including clinical data from TACTI-002 PhII trial, efficacy & tolerability data from INSIGHT-003 PhI trial & progress on its late stage & registrational trials.
#LAG3 #immunotherapy $IMM $IMMP
ASX: bit.ly/47ZWFXI

From everyone at Immutep, we'd like to thank you for your support throughout the year.

Wishing you and your families a very joyous holiday period and we look forward to continuing our momentum in 2024.